×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Immunotherapy

Brielle Urciuoli
Traditionally, desmoplastic melanoma was difficult to treat because the tumor tissue is so dense. However, researchers just discovered that immunotherapy agents have potential in this space.
Adam M. Brufsky, MD, PhD, and Lynn Acierno, BSN, RN, OCN, RN-BC, discuss how their team overcomes challenges in diagnosing and treating triple-negative breast cancer.
Brielle Urciuoli
To date, trials testing the use of immunotherapy in the treatment of ovarian cancer yielded disappointing results. However, researchers are not giving up. Instead, they’re investigating to see if immunotherapy drugs – such as PD1 and PDL-1 inhibitors – can be combined with other agents to benefit patients.
Danielle Bucco
Ferdinandos Skoulidis, M.D., Ph.D. highlights potential treatment options for KRAS-mutated lung cancer and explores developments in biomarker research in other areas in the field.
Gina Columbus
Checkpoint inhibitors continue to show promise in the treatment of patients with non-small cell lung cancer (NSCLC), but researchers are now exploring the efficacy of these agents when combined with radiation therapy (RT).
 
Danielle Bucco
When combined with other regimens in the treatment of patients with bladder cancer, immunotherapy has been shown to be beneficial, according to Arjun Balar, M.D.
Justin Chura, MD, discusses his initial approach to treating ovarian cancer. Anya Khomenko, survivor of ovarian cancer, advises patients on how to become educated on new therapeutic options and prepare for follow-up appointments.
Lisa Astor
Treatment with Opdivo (nivolumab) plus Yervoy (ipilimumab) improved response rates in patients with melanoma, but not without some severe side effects.
Angelica Welch
Marina C. Garassino, M.D., talks about exciting advances in the field of lung cancer.
Angelica Welch
Clinical trials of combination immunotherapy treatments are showing impressive overall survival rates.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable